<DOC>
	<DOCNO>NCT00493532</DOCNO>
	<brief_summary>This single arm study ass efficacy safety quarterly intravenous Bonviva woman post-menopausal osteoporosis . All patient receive Bonviva 3mg i.v . every 3 month . The anticipated time study treatment 3-12 month , target sample size 100 individual .</brief_summary>
	<brief_title>A Study Quarterly Intravenous Bonviva ( Ibandronate ) Women With Post-Menopausal Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>postmenopausal woman osteoporosis ; &lt; =80 year age ; naive oral bisphosphonates , discontinue daily and/or weekly bisphosphonate treatment &gt; 1 year . metabolic bone disease postmenopausal osteoporosis ; treatment drug affect bone metabolism within last 6 month ; previous current malignant disease ( except adequately treated cancer situ cervix , basal squamous cell skin cancer ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>